ANDA 214596, held by Cipla. Phytonadione.
As of Nov 15, 2026, ANDA 214596 (Phytonadione), held by Cipla, was first approved by FDA on Apr 22, 2022, with 0 approved supplements and 0 published complete response letters.
Phytonadione injectable emulsion is a vitamin K replacement indicated for the treatment of the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity. Anticoagulant-induced hypoprothrombinemia deficiency caused by coumarin or indanedione derivatives; Hypoprothrombinemia due to antibacterial therapy; Hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 22, 2022 | Original application | Approved |
| Phytonadione1MG/0.5ML · injectable;injection | Phytonadione | Rx |
| Phytonadione10MG/ML · injectable;injection | Phytonadione | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
